Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
PepGen Went Public On 5 May As Well
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
You may also be interested in...
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Deal Snapshot: The licensing deal worth up to $905m is on top of the companies’ existing partnership to develop BBP-398 together with BMS’s PD-1 inhibitor Opdivo and shows growing pharma interest in SHP2.
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.